Invitrogen™ Human IL-27 p28 Synthetic Peptide
IL-27 Synthetic Peptide, PEP-0359, from Invitrogen.
- Gene ID (Enter)
- 246778
- Species
- Human
- Purification method
- Purified
- Accession number
- Q8NEV9
- Common name
- Human IL-27
- Brand
- Invitrogen
IL-27 Synthetic Peptide, PEP-0359, from Invitrogen.
IL-27 Synthetic Peptide, PEP-0359, from Invitrogen.
IL-27, a member of the IL-12 family, is a heterodimeric protein consisting of the p40-related protein Epstein-Barr virus-induced gene 3 (EBI3) non-covalently linked to an IL-12p35-related protein, p28 (also known as IL-30). IL-27 is produced by activated APCs and mature dendritic cells. IL-27 exerts its activities on NK cells and naive CD4+ T cells; mRNA expression analysis of IL-27 receptor components (WSX-1/TCCR and gp130) suggests that IL-27 may also target other cells, including mast cells and monocytes. Binding of IL-27 to WSX-1/gp130 activates JAK1, STAT1, and STAT3 and STAT1/3 phosphorylation. WSX-1/TCCR-deficient mice develop impaired Th1 responses and are more susceptible to infection with L. monocytogenes suggesting that Th1 responses require IL-27. Although activation of WSX-1 is required for the initiation of Th1 responses, it is not necessary for maintaining Th1 responses. IL-27 alone is not able to induce the differentiation of CD4+ T cells into IFN-γ-producing cells, suggesting a role for IL-27 as an initial activator of Th1 responses. An important effect of IL-27 in initiating Th1 responses is the induction of the Th1-specific transcription factor T-bet as well as the suppression of the Th2-specific transcription factor GATA-3. T-bet plays a critical role in Th1 differentiation by its ability to maintain IL-12Rβ2 expression following CD4+ T cell activation. Recent studies indicate that IL-27 has a potent antitumor activity. In vitro, IL-27 has been found to act directly on naive CD8 cells, generating CTL with enhanced granzyme B expression. In vivo, IL-27 has been reported to augment CTL activity, inhibit tumor growth, and induce complete regression of primary and metastatic neuroblastoma tumors.
Species: Human.
Storage: -20°C.
Concentration: 200 μg/mL.
Research only (RUO).
Packaging: 50 μg.
| General | |
|---|---|
| Brand | Invitrogen |
| Supplier ref. (Fisher Scientific) | 15266569 |
| Specifications | |
| Gene ID (Enter) | 246778 |
| Species | Human |
| Purification method | Purified |
| Accession number | Q8NEV9 |
| Common name | Human IL-27 |
| Concentration | 200 μg/mL |
| Description | Synthetic Peptide |
| Format | Liquid |
| Formula | PBS with 0.1% BSA and 0.02% sodium azide; pH 7.2 |
| For use with (application) | Blocking Assay, Control |
| Gene symbol(s) | IL27 |
| Lyophilized | No |
| Product type | Peptide |
| Quantity | 50 μg |
| Regulatory status | RUO - research use only |
| Storage and shipping | |
| Content and storage | -20°C |
| Conservative | 0.02% sodium azide |
| Storage stamp | PBS |
| Manufacturer ref. | PEP-0359 |
|---|---|
| Country of origin | United States |
| HS customs code | 3824 99 96 00 |